相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Lisi Deng et al.
BMC INFECTIOUS DISEASES (2022)
Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice
Simone Belmonti et al.
DIAGNOSTICS (2022)
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection
Pedro Cahn et al.
AIDS (2022)
Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults
Ines Mendoza et al.
ANNALS OF PHARMACOTHERAPY (2022)
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
Charlotte-Paige Rolle et al.
AIDS (2021)
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice
Arturo Ciccullo et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2020)
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naive, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety
Valeria Cento et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
Pedro Cahn et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis
Joseph Eron et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
Rosa De Miguel et al.
EBIOMEDICINE (2020)
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
L. Ryom et al.
HIV MEDICINE (2020)
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2020 Recommendations of the International Antiviral Society-USA Panel
Michael S. Saag et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial
Delphine Sculier et al.
PLOS MEDICINE (2020)
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients
Gianmaria Baldin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
Alberto Borghetti et al.
BMC INFECTIOUS DISEASES (2019)
HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients
Jonathan L. Golob et al.
AIDS (2018)
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication
A. Borghetti et al.
HIV MEDICINE (2018)
Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance
Bluma G. Brenner et al.
VIRUS RESEARCH (2017)
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
Pedro Cahn et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2017)
Evaluation of Serum Creatinine Changes With Integrase Inhibitor Use in Human Immunodeficiency Virus-1 Infected Adults
Tara A. Lindeman et al.
OPEN FORUM INFECTIOUS DISEASES (2016)
HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy
Guillaume J. Besson et al.
CLINICAL INFECTIOUS DISEASES (2014)
Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
Mackenzie L. Cottrell et al.
CLINICAL PHARMACOKINETICS (2013)
分享论文
